Vor Biopharma (VOR) News Today $1.37 -0.03 (-2.14%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.36%) As of 02/21/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Vor Bio presents research on patients participating in CGT trialsFebruary 13, 2025 | markets.businessinsider.comVor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy TrialsFebruary 13, 2025 | globenewswire.comVor biopharma's chief medical officer sells $3,498 in stockFebruary 12, 2025 | msn.comVor Biopharma revises stock option exercise pricesFebruary 6, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by BrokeragesShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have coveFebruary 5, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Shares Down 5.6% - What's Next?Vor Biopharma (NYSE:VOR) Trading Down 5.6% - Here's What HappenedFebruary 4, 2025 | marketbeat.comVor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comVor Bio files to sell 125.71M shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have received a consensus rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price objective amongJanuary 11, 2025 | marketbeat.comVor Bio appoints Kalir to board of directorsJanuary 8, 2025 | markets.businessinsider.comVor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of DirectorsJanuary 8, 2025 | globenewswire.comEyal C. Attar Sells 10,334 Shares of Vor Biopharma Inc. (NYSE:VOR) StockJanuary 1, 2025 | insidertrades.comVor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in StockVor Biopharma Inc. (NYSE:VOR - Get Free Report) insider Eyal C. Attar sold 10,334 shares of the business's stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the completion of the transaction, the insider now directly owns 81,439 shares of the company's stock, valued at approximately $101,798.75. This trade represents a 11.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.December 31, 2024 | marketbeat.comVor Bio price target lowered to $6 from $12 at JMP SecuritiesDecember 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Precigen (PGEN), Vor Biopharma (VOR)December 27, 2024 | markets.businessinsider.comVor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%December 27, 2024 | finance.yahoo.comVor Bio Announces $55.6 Million Private PlacementDecember 27, 2024 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by AnalystsVor Biopharma Inc. (NYSE:VOR - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among analysts thatDecember 17, 2024 | marketbeat.comPositive Outlook for Vor Biopharma’s Trem-cel in AML Trials Leads to Buy RatingDecember 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Vor Biopharma Based on Promising Clinical Trial Developments and Strong Financial PositionDecember 10, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Vor Biopharma (VOR)December 10, 2024 | markets.businessinsider.comVor Biopharma’s Strategic Advances and Promising Clinical Trial Results Justify Buy RatingDecember 10, 2024 | markets.businessinsider.comVor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial DesignDecember 9, 2024 | globenewswire.comVor Biopharma’s Promising Clinical Trials and Strategic Planning Earn a Buy RatingNovember 11, 2024 | markets.businessinsider.comVor Biopharma’s Trem-cel Therapy Shows Promise with Positive Patient Dosing and Upcoming Data PresentationNovember 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR) and Sight Sciences (SGHT)November 9, 2024 | markets.businessinsider.comVor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushWedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Vor Biopharma in a research report on Friday.November 8, 2024 | marketbeat.comVor Biopharma's (VOR) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Friday.November 8, 2024 | marketbeat.comRobert W. Baird Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock PriceRobert W. Baird cut their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a report on Friday.November 8, 2024 | marketbeat.comVor Bio Reports Third Quarter 2024 Financial Results and Provides Company UpdateNovember 7, 2024 | markets.businessinsider.comVor Biopharma (NASDAQ:VOR) Stock, Option ChainNovember 2, 2024 | benzinga.comVor Biopharma: Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerSeptember 30, 2024 | finanznachrichten.deVor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerSeptember 30, 2024 | globenewswire.comXbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)September 27, 2024 | finanznachrichten.deEvercore ISI Keeps Their Buy Rating on Vor Biopharma (VOR)September 8, 2024 | markets.businessinsider.comVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among analystSeptember 8, 2024 | marketbeat.comVor Biopharma (VOR) Receives a Buy from BarclaysSeptember 6, 2024 | markets.businessinsider.comVor Biopharma’s Promising Clinical Trials and Strategic Developments Merit a Buy RatingSeptember 6, 2024 | markets.businessinsider.comWhat's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?September 6, 2024 | msn.comVor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday.September 6, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday.September 6, 2024 | marketbeat.comNew Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 6, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Strategic Acquisitions Bolster Buy Rating for Vor BiopharmaSeptember 6, 2024 | markets.businessinsider.comNew Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 5, 2024 | globenewswire.comHere's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash WiselySeptember 5, 2024 | finance.yahoo.comVor Bio to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Buy" from AnalystsVor Biopharma Inc. (NYSE:VOR - Get Free Report) has earned an average rating of "Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokeraAugust 14, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Price Target Lowered to $3.00 at BarclaysBarclays dropped their price target on Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating for the company in a research note on Wednesday.August 14, 2024 | marketbeat.comBuy Rating Backed by Clinical and Financial Strengths at Vor BiopharmaAugust 13, 2024 | markets.businessinsider.comOptimistic Outlook on Vor Biopharma’s Pipeline and Financial Stability Drives Buy RatingAugust 9, 2024 | markets.businessinsider.com Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address VOR Media Mentions By Week VOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼-1.000.60▲Average Medical News Sentiment VOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼11▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRME News Today ESPR News Today RGNX News Today TRML News Today MBX News Today ACB News Today TERN News Today FHTX News Today TSHA News Today CYRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts